ACE2 has a pivotal role for the infection of SARS-CoV-2: it is recognized by the viral spike protein leading to the entry of the virus into cells. Differently from current monoclonal antibodies strategies, an innovative idea is based on the possibility of binding and shielding ACE2 instead of spike protein, avoiding problems related to the outbreak of viral variants. By using the yeast display technology, synthetic and alpaca-derived nanobodies are exploited as binders towards ACE2. The selection process is carried out through fluorescence-activated cell sorting while the increase of affinity for the synthetic nanobodies is performed through affinity maturation process.
DIRECTED EVOLUTION OF THERAPEUTIC PROTEINS USING YEAST DISPLAY TECHNOLOGY
CINELLO, GIACOMO
2021/2022
Abstract
ACE2 has a pivotal role for the infection of SARS-CoV-2: it is recognized by the viral spike protein leading to the entry of the virus into cells. Differently from current monoclonal antibodies strategies, an innovative idea is based on the possibility of binding and shielding ACE2 instead of spike protein, avoiding problems related to the outbreak of viral variants. By using the yeast display technology, synthetic and alpaca-derived nanobodies are exploited as binders towards ACE2. The selection process is carried out through fluorescence-activated cell sorting while the increase of affinity for the synthetic nanobodies is performed through affinity maturation process.| File | Dimensione | Formato | |
|---|---|---|---|
|
Cinello_Giacomo.pdf
accesso riservato
Dimensione
2.33 MB
Formato
Adobe PDF
|
2.33 MB | Adobe PDF |
The text of this website © Università degli studi di Padova. Full Text are published under a non-exclusive license. Metadata are under a CC0 License
https://hdl.handle.net/20.500.12608/42312